Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invictus MD Strategies Corp IVITF

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.


GREY:IVITF - Post by User

Comment by Yowza123on Aug 14, 2019 3:53pm
90 Views
Post# 30028725

RE:Reality

RE:Reality


Invictus released its cost per gram in a June news release to be $5.95 gram/ cdn. Hopefully when the German Demecan deal finally goes through we might see this average back up.

Vancouver, BC, June 12, 2019 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) 
Mr. Trevor Dixon, Chief Executive Officer of Invictus, is pleased to report that the Phase I and II facilities of the Company’s wholly owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms”), comprising a total of 40,000 sq. ft of combined space, are now in full production and is commencing the third harvest cycle from their eleven flowering rooms.  Phase II was licensed for production under Health Canada’s Access to Cannabis for Medical Purposes Regulations(“ACMPR“) on August 31, 2018 and is currently harvesting four room harvests per month.  Total production has now reached over 200 kg per month of dry bud and dry cannabis for Acreage Pharms’ in-house CO2 critical gas extraction. Phase I and II are meeting the planned production of 2,400 kg per year. Acreage Pharms is averaging a price of $5.95 per gram sold of dry bud.

On Behalf of the Board
Trevor Dixon
Chief Executive Officer

<< Previous
Bullboard Posts
Next >>